Business Wire · XTEN · October 14, 2026

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Get the app for more

Explore stock news, insights and company research.